Onesource Specialty Pharma Share Price
1575.70+0.00 (+2.03%)
-17.02% past 1 Year
News
Onesource Specialty Pharma posts higher Q1 EBITDA and stable margin
Equity
ONESOURCE
Onesource Specialty Pharma reports higher Q1 revenue at Rs 446 crores
Equity
ONESOURCE
Onesource Specialty Pharma Q1 net profit more than doubles year-on-year
Equity
ONESOURCE
Onesource Specialty Pharma, Formycon AG sign biosimilars manufacturing partnership
Equity
ONESOURCE
Onesource Specialty Pharma says Dr Reddys supply delay non-disruptive, expansion on track
Equity
ONESOURCE
Onesource Specialty Pharma sterile unit clears USFDA audit with minor note
Equity
ONESOURCE
Onesource Specialty Pharma informs about updates
Equity
ONESOURCE
Onesource Specialty - Quaterly Results
Equity
ONESOURCE
Onesource Specialty Pharma informs about outcome of board meeting
Equity
ONESOURCE
Onesource Specialty reports Profit after tax of 21.48 Crores, in the March 2026 quarter
Equity
ONESOURCE
Onesource Specialty Pharma Q4 Results: EBITDA Declines 69% YoY
Equity
ONESOURCE
Onesource Specialty Pharma Q4 FY2026 Revenue Decline YoY
Equity
ONESOURCE
Onesource Specialty Pharma Q4 Net Profit Declines 87.8% YoY to Rs 21.40 Crores
Equity
ONESOURCE
OneSource Specialty Pharma informs about press release
Equity
ONESOURCE
OneSource Specialty’s partner gets Health Canada nod for generic version of Ozempic
Equity
ONESOURCE
Onesource Specialty Pharma Backs Canada's Approval of Second Generic Semaglutide.
Equity
ONESOURCE
Onesource Specialty Identifies Semaglutide as Key Opportunity and Canada as Significant Market.
Equity
ONESOURCE
OneSource Specialty Pharma informs about press release
Equity
ONESOURCE
OneSource Specialty Pharma shines on securing EU GMP certificate for SPD facility
Equity
ONESOURCE
Onesource Specialty’s partner gets Health Canada nod for Generic Semaglutide Injection
Equity
ONESOURCE